New targeted drug shows promise for rare cancer mutation
NCT ID NCT06533059
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 36 times
Summary
This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tried other treatments first or not been able to take them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
La Jolla, California, 92093, United States
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Maumee, Ohio, 43637, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Madison, Wisconsin, 53792, United States
-
Research Site
Blacktown, New South Wales, 2148, Australia
-
Research Site
Randwick, New South Wales, 2031, Australia
-
Research Site
South Brisbane, Queensland, 4101, Australia
-
Research Site
Malvern, Victoria, 3144, Australia
-
Research Site
Nedlands, Western Australia, 6009, Australia
-
Research Site
Caen, 14000, France
-
Research Site
Dijon, 21000, France
-
Research Site
Saint-Herblain, 44805, France
-
Research Site
Villejuif, 94800, France
-
Research Site
Kyoto, 606-8507, Japan
-
Research Site
Matsuyama, 791-0280, Japan
-
Research Site
Shizuoka, 411-8777, Japan
-
Research Site
Tokyo, 135-8550, Japan
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 13620, South Korea
-
Research Site
Barcelona, 08023, Spain
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Barcelona, 08908, Spain
-
Research Site
Madrid, 28023, Spain
-
Research Site
Madrid, 28040, Spain
-
Research Site
Valencia, 46010, Spain
-
Research Site
Changhua, 500, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taipei, 10449, Taiwan
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
London, W1G 6AD, United Kingdom
-
Research Site
London, W1T 7HA, United Kingdom
-
Research Site
Manchester, M10 4BX, United Kingdom
-
Research Site
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
-
Research Site #2
San Antonio, Texas, 78229, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.